SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1484)3/10/2000 12:39:00 PM
From: biowa  Read Replies (1) | Respond to of 2001
 
Peter,

Note also AVAN's complement inhibitor program, partially partnered and also in the clinic. Not evaluating, just noting.

biowa



To: Biomaven who wrote (1484)3/10/2000 12:50:00 PM
From: Dr. John M. de Castro  Respond to of 2001
 
Thanks Peter! GLIA's tactic is to go after the protein properdin. The properdin MAB stops the alternate complement pathway that is activated in disease states and leaves the classical pathway alone. Alexions approach, if I understand all this correctly, blocks a late stage molecule C5 in the complement cascade. I'm sure there are people more knowledgeable than I that could comment on the relative merits of the two approaches.

Best regards
John de C


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News